内镜颅底手术后需内镜鼻窦手术的发生率、危险因素与结局
术后25%需再次内镜鼻窦手术,平均间隔42个月;恶性肿瘤、化疗和放疗与再手术需求相关,SNOT-22评分显著改善。
要点
- 内镜颅底手术后约25%患者需再次内镜鼻窦手术,平均间隔42个月。
- 恶性肿瘤、化疗和放疗是再次内镜鼻窦手术的危险因素。
- 术后SNOT-22评分较术前显著改善,但Lund-Mackay评分无显著变化。
核心结论
- 鼻腔鼻窦与颅底同时受累的肿瘤患者在内镜颅底手术后,相当比例出现临床显著鼻窦炎并可能受益于再次内镜鼻窦手术。
- 再次手术平均发生在初次肿瘤切除后3.5年,恶性肿瘤、放疗和化疗与再手术需求相关。
研究设计与样本
- 主要结局指标包括再次手术的发生率和时机、Lund-Mackay评分和22项鼻鼻窦结局测试(SNOT-22)评分。
主要发现
- 初次切除至再次手术的平均时间为42个月(范围6至142个月)。
- 颅底手术前后Lund-Mackay评分无显著差异(5.0 vs 4.7,p=0.640)。
- 颅底手术前后SNOT-22评分显著改善(32.6 vs 24.5,p=0.030)。
- 恶性肿瘤与再次内镜鼻窦手术需求相关(比值比[OR] 5.07,p=0.04),化疗(OR 5.10,p=0.003)和放疗(OR 4.15,p=0.013)亦相关。
临床怎么用
- 对鼻腔鼻窦与颅底同时受累的肿瘤患者,内镜颅底手术后应关注鼻窦炎症状,必要时评估再次内镜鼻窦手术。
- 恶性肿瘤、接受化疗或放疗的患者再次手术风险较高,应加强术后随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing endoscopic resection of neoplasms with both sinonasal and skull base involvement can develop chronic rhinosinusitis (CRS) after treatment and may occasionally benefit from additional endoscopic sinus surgery (ESS). We investigate risk factors and outcomes associated with revision ESS (rESS) after endoscopic skull-base surgery (SBS) for neoplasms with combined sinonasal and skull base involvement. METHODS: A retrospective review of patients with neoplasms with both sinonasal and skull base involvement who underwent endoscopic resection at a single tertiary care academic institution from 2004 through 2017 was performed. Eighty-three patients were included. Main outcome measures included incidence and timing of revision surgery, Lund-Mackay (LM) scores, and 22-item Sino-Nasal Outcome Test (SNOT-22) scores. RESULTS: rESS was performed in 21 (25%) cases, 15 (18%) of which were due to CRS. Time between initial resection and rESS was an average of 42 months (range, 6 to 142 months). Pre-SBS and post-SBS LM scores were not significantly different (5.0 vs 4.7, p = 0.640), although pre-SBS and post-SBS SNOT-22 scores showed significant improvement (32.6 vs 24.5, p = 0.030). Malignant pathology correlated with need for rESS (odds ratio [OR] 5.07, p = 0.04), as well as treatment including chemotherapy (OR 5.10, p = 0.003) and radiation (OR 4.15, p = 0.013). CONCLUSION: A significant proportion of patients develop clinically significant sinusitis after endoscopic SBS for neoplasms with combined sinonasal and skull base involvement and may benefit from rESS. Intervention occurred, on average, 3.5 years after initial tumor resection. Malignant pathology, radiation therapy, and chemotherapy correlate with need for rESS.
引用
- Shah RR, Maina IW, Patel NN, et al. Incidence, risk factors, and outcomes of endoscopic sinus surgery after endoscopic skull-base surgery. Int Forum Allergy Rhinol. 2020. PMID: 32104979. doi:10.1002/alr.22486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。